How do we turn complex technology challenges into simpler solutions for patients? By designing with intention to remove bottlenecks and build platforms that can adapt across diseases. This approach is guided by our co-founder, President, and Chief Scientific Officer, George D. Yancopoulos, whose five principles of radical innovation shape how we think, design, and build. Created to cut through complexity, our proprietary Veloci-Bi® technology allows for production of bispecific antibodies, which